Download MendeleyStructural Basis of Cysteine Ligase MshC Inhibition by Cysteinyl-Sulfonamides.
Pang, L., Lenders, S., Osipov, E.M., Weeks, S.D., Rozenski, J., Piller, T., Cappoen, D., Strelkov, S.V., Van Aerschot, A.(2022) Int J Mol Sci 23
- PubMed: 36499418
- DOI: https://doi.org/10.3390/ijms232315095
- Primary Citation of Related Structures:
8HFM, 8HFN, 8HFO - PubMed Abstract:
Mycothiol (MSH), the major cellular thiol in Mycobacterium tuberculosis (Mtb), plays an essential role in the resistance of Mtb to various antibiotics and oxidative stresses. MshC catalyzes the ATP-dependent ligation of 1- O -(2-amino-2-deoxy-α-d-glucopyranosyl)-d- myo -inositol (GlcN-Ins) with l-cysteine (l-Cys) to form l-Cys-GlcN-Ins, the penultimate step in MSH biosynthesis. The inhibition of MshC is lethal to Mtb. In the present study, five new cysteinyl-sulfonamides were synthesized, and their binding affinity with MshC was evaluated using a thermal shift assay. Two of them bind the target with EC 50 values of 219 and 231 µM. Crystal structures of full-length MshC in complex with these two compounds showed that they were bound in the catalytic site of MshC, inducing dramatic conformational changes of the catalytic site compared to the apo form. In particular, the observed closure of the KMSKS loop was not detected in the published cysteinyl-sulfamoyl adenosine-bound structure, the latter likely due to trypsin treatment. Despite the confirmed binding to MshC, the compounds did not suppress Mtb culture growth, which might be explained by the lack of adequate cellular uptake. Taken together, these novel cysteinyl-sulfonamide MshC inhibitors and newly reported full-length apo and ligand-bound MshC structures provide a promising starting point for the further development of novel anti-tubercular drugs targeting MshC.
Organizational Affiliation:
Research Center of Basic Medicine, Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou 450001, China.
